Latest Daily News

More Stories

June 6, 2017

Researchers presented results of four studies evaluating new approaches to targeted therapies for patients with lung cancer, including metastatic non–small cell lung cancer.

Read more
June 5, 2017

Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.

Read more
June 3, 2017

Dr. James P. Allison and Dr. Suzanne L. Topalian highlighted the transformative nature of immune checkpoint inhibitors on cancer treatment and outlined a roadmap for future research.

Read more

June 3, 2017

Dr. Jeffrey Weber discusses how lessons learned from the use of checkpoint inhibitors in melanoma can be applied to immunotherapy for other cancers.

Read more
June 2, 2017

Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy at the Perelman School of Medicine, University of Pennsylvania, has been honored with the 2017 David A. Karnofsky Memorial Award.

Read more

June 2, 2017

Dr. Siddhartha Mukherjee will serve as the guest speaker at this year’s Opening Session for the 2017 ASCO Annual Meeting.

Read more
May 25, 2017

The 3 mg/kg dose is considered the “standard” dose of ipilimumab, however, there has continued to be debate in the field about the most appropriate dose of ipilimumab, and clinical trials have continued to investigate the 10 mg/kg dose.

Read more
May 25, 2017

Exploring the benefit the of ipilimumab in the second-line setting for metastatic melanoma.

Read more

May 25, 2017

The 2011 ASCO Annual Meeting Plenary Session ushered in a renaissance for melanoma therapy with the promise of targeted therapy. Results of the BRIM-3 trial marked the beginning of the end of cytotoxic chemotherapy for melanoma.

Read more
April 7, 2017

The 2017 Clinical Immuno-Oncology Symposium achieved a successful first year, in which 950 physicians, researchers, translation-oriented scientists, and others gathered to learn about state-of-the-art developments in the science and application of immuno-oncology. 

Read more